Jazz Pharmaceuticals Stock Analysis & Ratings
0 Followers
J7Z Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range― - ―
Previous Close€150.52
Volume0.00
Average Volume (3M)22.00
Market CapN/A
Enterprise ValueN/A
P/E RatioN/A
Beta0.08
Next EarningsNov 08, 2022
EPS Forecast€4.54
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price Target€193.50
Smart Score3
EPS (TTM)N/A
Shares Outstanding62,442,548
R-SquaredN/A
Standard DeviationN/A
10 Day Avg. Volume0
30 Day Avg. Volume22
P/B Ratio-2.00
P/S Ratio3.79
P/CF Ratio13.80
P/FCF Ratio16.90
Total Debt€2.03B
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/EbitdaN/A
Price Target Upside28.55% Upside
Rating ConsensusStrong Buy
AlphaN/A
Number of Analyst Covering10
Jazz Pharmaceuticals News
P/E Ratio Range
The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.
---
J7Z FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Currently, no data Available
What is Jazz Pharmaceuticals’s market cap?
Currently, no data Available
What is Jazz Pharmaceuticals’s price target?
The average price target for Jazz Pharmaceuticals is €193.50. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is €209.48 ,the lowest forecast is €178.30. The average price target represents 28.55% Increase from the current price of €150.52.
The highest analyst price target is €209.48 ,the lowest forecast is €178.30. The average price target represents 28.55% Increase from the current price of €150.52.
What do analysts say about Jazz Pharmaceuticals?
Jazz Pharmaceuticals’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Nov 08, 2022 which is in 86 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Aug 03, 2022. The company reported €4.19 earnings per share for the quarter, beating the consensus estimate of €4.071 by €0.119.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is €4.54.
How many shares outstanding does Jazz Pharmaceuticals have?
Currently, no data Available
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of €4.19 in its last earnings report, beating expectations of €4.071. Following the earnings report the stock price went down -0.414%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Among the largest hedge funds holding Jazz Pharmaceuticals’s share is Polaris Capital Management LLC. It holds Jazz Pharmaceuticals’s shares valued at 234M.
---
Jazz Pharmaceuticals Stock Analysis
Smart ScoreUnderperform
1
2
3
4
5
6
7
8
9
10
Analyst Forecast
Strong Buy
Average Price Target: €193.50
Blogger Sentiment
Bullish
DE:J7Z Sentiment 75% Sector Average 69%
Insider Transactions
▼ Sold Shares
Worth $7.6M over the Last 3 Months
News Sentiment
Neutral
Bullish 100% Bearish 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
7.84%
12-Months-Change
Fundamentals
Return on Equity
-1.41%
Trailing 12-Months
Asset Growth
-15.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
Endo International
―
Iterum Therapeutics
―
Perrigo Company
―
GH Research
―
Avadel Pharmaceuticals
―
---